Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04597970
Other study ID # 2020YJZ41
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 20, 2020
Est. completion date October 20, 2022

Study information

Verified date October 2020
Source Beijing Cancer Hospital
Contact Xu Zhu
Phone 86-01088196059
Email drzhuxu@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose:explore the effectiveness and safety of transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)


Description:

Thhis is a non-randomized, open, single-arm clinical study. patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle, until the disease progresses, intolerable toxicity occurs, the patient is lost to follow-up or death, or situations other judged by researchers which treatment should be stopped. Number of patients: 66 patients End points:primary end points:safety 、objective response rate,disease control rate,progression free overall survival,second end point :overall survival Include criteria: 1. Volunteer to participate and sign the informed consent in writing; 2. Age: 18-75 years old; 3. No gender limit; 4. BCLC stage C hepatocellular carcinoma with pathological diagnosis or clinical diagnosis; 5. Barcelona stage C patients who failed first-line treatment (including but not limited to sorafenib, levatinib, atelizumab combined with bevacizumab, etc.); they have not received sorafenib in the past The patients treated by Sorafenib can receive sorafenib treatment at the same time, and the patients who have received sorafenib treatment progress can also receive regorafenib treatment. 6. At least one measurable lesion (according to mRECIST criteria) imaging diagnosis time ≤ 21 days from selection; 7. Child-pugh grade A-B7 grade 8. The expected survival period is ≥3 months; 9. ECOG Performance Status (ECOG) 0-2; 10. Sufficient bone marrow hematopoietic function (within 7 days): hemoglobin ≥9 g/dL, white blood cells ≥3.0×109/L, neutrophils ≥1.5x109/L, platelets ≥80x109/L; liver and kidney functions are normal (Within 14 days): TBIL≤1.5 times the upper limit of normal; ALT and AST≤5 times the upper limit of normal; creatinine≤1.5 times the upper limit of normal; INR<1.7 or prolonged PT<4s Exclude criteria: 1. Those who are currently receiving other effective treatments; 2. Patients who have received oxaliplatin and raltitrexed in the past; 3. Patients who have participated in other clinical trials within 4 weeks before enrollment; 4. Unable to cooperate with cTACE and HAIC treatment; 5. Patients with primary malignant tumors other than hepatocellular carcinoma at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ; 6. Clinically significant cardiovascular diseases, such as heart failure (NYHA III-IV), uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, uncontrolled hypertension or a history of myocardial infarction within the past 1 year; 7. Neurological or mental abnormalities that affect cognitive ability, including central nervous system transfer; 8. There were active serious clinical infections (>grade 2 NCI-CTCAE version 4.0), including active tuberculosis within 14 days before enrollment; 9. Known or self-reported HIV infection; 10. Uncontrolled systemic diseases, such as poorly controlled diabetes; 11. Known to have hypersensitivity or allergic reactions to any component of the study drug; 12. Pregnancy (determined by serum β-chorionic gonadotropin test) or breast-feeding Treatment:patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle, until the disease progresses, intolerable toxicity occurs, the patient is lost to follow-up or death, or situations other judged by researchers which treatment should be stopped.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 66
Est. completion date October 20, 2022
Est. primary completion date October 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Volunteer to participate and sign the informed consent in writing; 2. Age: 18-75 years old; 3. No gender limit; 4. BCLC stage C hepatocellular carcinoma with clear pathological diagnosis or clinical diagnosis; 5. Barcelona stage C patients who failed first-line treatment (including but not limited to sorafenib, levatinib, atelizumab combined with bevacizumab, etc.); they have not received sorafenib in the past The patients treated by Sorafenib can receive sorafenib treatment at the same time, and the patients who have received sorafenib treatment progress can also receive regorafenib treatment. 6. At least one measurable lesion (according to mRECIST criteria) imaging diagnosis time = 21 days from selection; 7. Child-pugh grade A-B7 grade 8. The expected survival period is =3 months; 9. General physical condition (ECOG) 0-2; 10. Sufficient bone marrow hematopoietic function (within 7 days): hemoglobin =9 g/dL, white blood cells =3.0×109/L, neutrophils =1.5x 109/L, platelets =80x 109/L; liver and kidney functions are normal (Within 14 days): TBIL=1.5 times the upper limit of normal; ALT and AST=5 times the upper limit of normal; creatinine=1.5 times the upper limit of normal; INR<1.7 or prolonged PT<4s Exclusion Criteria: 1. Those who are currently receiving other effective treatments; 2. Patients who have received oxaliplatin and raltitrexed in the past; 3. Patients who have participated in other clinical trials within 4 weeks before enrollment; 4. Unable to cooperate with cTACE and HAIC treatment; 5. Patients with primary malignant tumors other than hepatocellular carcinoma at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ; 6. Clinically significant cardiovascular diseases, such as heart failure (NYHA III-IV), uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, uncontrolled hypertension or a history of myocardial infarction within the past 1 year; 7. Neurological or mental abnormalities that affect cognitive ability, including central nervous system transfer; 8. There were active serious clinical infections (>grade 2 NCI-CTCAE version 4.0), including active tuberculosis within 14 days before enrollment; 9. Known or self-reported HIV infection; 10. Uncontrolled systemic diseases, such as poorly controlled diabetes; 11. Known to have hypersensitivity or allergic reactions to any component of the study drug; 12. Pregnancy (determined by serum ß-chorionic gonadotropin test) or breast-feeding

Study Design


Intervention

Drug:
cTACE-HAIC
transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Beijing Cancer Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate, ORR The objective response rate (ORR) was defined as the complete response (CR) rate + the partial response (PR) rate 6 months
Primary Disease control rate, DCR disease control rate (DCR) was defined as the CR rate + the PR rate + the stable disease (SD) rate 6 months
Primary Progression free overall survival,PFS PFS was defined as the interval between the time at which treatment was initiated and intrahepatic tumor and/or extrahepatic tumor progression, symptomatic progression, including massive ascites and liver function that was categorized as Child-Pugh grade C, or death from any cause 8 months
Secondary Overall survival, OS overall survival (OS) was defined as the interval between the time at which treatment was initiated and death or the last follow-up assessment 25 months
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2